Replies to post #795573 on NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Correct! Massive revenues are NOT a prerequisite for Wall-Street investment. Thank you.

I did not miss the important point regarding management credibility. MHRA approval and multiple Big Pharma partnerships are the very definition of credibility. What do you think they signal? Linda Powers has steered NWBO through:

1. A global Phase 3 trial,
2. MHRA GMP and HTA licensing,
3. End-to-end manufacturing built from scratch—now fully owned and infinitely scalable via Eden,
4. Patent protection for dendritic cell maturation, the entire manufacturing process, and combo therapies,
5. Multiple BP partnerships with upfront cash.

All while absorbing relentless attacks from Wall Street spoofing/shorting and supposed shareholders like yourself. So yes—credibility is part of the market’s calculus. And NWBO has it in spades.

Massive revenues are not a pre-requisite, but if the management has credibility to deliver on potential future massive revenues is very important and is part of the calculus of how market determines current value